🇺🇸 FDA
Patent

US 9650447

Complement receptor 2 (CR2) targeting groups

granted A61PA61P1/04A61P11/06

Quick answer

US patent 9650447 (Complement receptor 2 (CR2) targeting groups) held by The Regents of the University of Colorado, a Body Corporate expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61P, A61P1/04, A61P11/06, A61P11/16, A61P13/12